Cross-neutralization Capacity of Immune Serum from Different Dosage of Sabin Inactivated Poliovirus Vaccine Immunization against Multiple Individual Polioviruses

References

• Global polio eradication initiative. Polio prevention. http://polioeradication.org/polio-today/polio-prevention/. Accessed 2021 Mar 28
   Google Scholar
• World Health Organization. Polio vaccines: WHO position paper – March, 2016. Vaccine. 2017;35(9): 1197–1199.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Polio vaccines and polio immunization in the pre-eradication era: WHO position paper. Wkly Epidemiol Rec. 2010;85(‎23):213–228. https://apps.who.int/iris/handle/10665/241584. Accessed 2020 Dec 12
   PubMedGoogle Scholar
• Zaffran M, McGovern M, Hossaini R, et al. The polio endgame: securing a world free of all polioviruses. Lancet. 2018;391(10115):11–13.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Polio eradication, report by the director-general. Paper presented at: Seventy-Second World Health Assembly; Geneva, 8 April 2019. https://apps.who.int/iris/handle/10665/328567. Accessed 2020 Dec 12
   Google Scholar
• Technical Consultative Group to the World Health Organization on the Global Eradication of Poliomyelitis. “Endgame” issues for the global polio eradication initiative. Clin Infect Dis. 2002;34(1): 72–77.
   PubMed Web of Science ®Google Scholar
• Garon J, Seib K, Orenstein WA, et al. Polio endgame: the global switch from tOPV to bOPV. Expert Rev Vaccines. 2016;15(6):693–708.
   PubMed Web of Science ®Google Scholar
• Platt LR, Estívariz CF, Sutter RW. Vaccine-associated paralytic poliomyelitis: a review of the epidemiology and estimation of the global burden. J Infect Dis. 2014;210(suppl 1):S380–9.
   PubMed Web of Science ®Google Scholar
• Estívariz CF, Watkins MA, Handoko D, et al. A large vaccine-derived poliovirus outbreak on Madura Island-Indonesia, 2005. J Infect Dis. 2008;197(3):347–354.
   PubMed Web of Science ®Google Scholar
• Jenkins HE, Aylward B, Gasasira A, et al. Implications of a circulating vaccine-derived poliovirus in Nigeria. New Engl J Med. 2010;362(25):2360–2369.
   PubMed Web of Science ®Google Scholar
• Tebbens RJD, Pallansch MA, Kim JH, et al. Oral poliovirus vaccine evolution and insights relevant to modeling the risks of circulating vaccine-derived polioviruses (cVDPVs). Risk Anal. 2013;33(4):680–702.
   PubMed Web of Science ®Google Scholar
• Dowdle W, Avoort HVD, Gourville ED, et al. Containment of polioviruses after eradication and OPV cessation: characterizing risks to improve management. Risk Anal. 2006;26(6):1449–1469.
   PubMed Web of Science ®Google Scholar
• Immunization Systems Management Group of the Global Polio Eradication Initiative. Cessation of trivalent oral poliovirus vaccine and introduction of inactivated poliovirus vaccine–worldwide. Morb Mortal Wkly. Rep. 2016;65(35):934–938.
   PubMed Web of Science ®Google Scholar
• Bakker WAM, Thomassen YE, Oever AG, et al. Inactivated polio vaccine development for technology transfer using attenuated Sabin poliovirus strains to shift from Salk-IPV to Sabin-IPV. Vaccine. 2011;29(41):7188–7196.
   PubMed Web of Science ®Google Scholar
• Sutter RW, Cochi SL. Inactivated poliovirus vaccine supply shortage: is there light at the end of the tunnel? J Infect Dis. 2019;220(10):1545–1546.
   PubMed Web of Science ®Google Scholar
• Okayasu H, Sutter RW, Jafari HS, et al. Affordable inactivated poliovirus vaccine: strategies and progress. J Infect Dis. 2014;210(suppl_1):S459–64.
   PubMed Web of Science ®Google Scholar
• Chu K, Ying Z, Wang L, et al. Safety and immunogenicity of inactivated poliovirus vaccine made from Sabin strains: a phase II, randomized, dose-finding trial. Vaccine. 2018;36(45):6782–6789.
   PubMed Web of Science ®Google Scholar
• Hu Y, Wang J, Zeng G, et al. Immunogenicity and safety of a Sabin strain-based inactivated polio vaccine: a phase 3 clinical trial. J Infect Dis. 2019;220(10):1551–1557.
   PubMed Web of Science ®Google Scholar
• Hu YM, Xu KW, Han WX, et al. Safety and Immunogenicity of Sabin strain inactivated poliovirus vaccine compared with salk strain inactivated poliovirus vaccine, in different sequential schedules with bivalent oral poliovirus vaccine: randomized controlled noninferiority clinical trials in China. Open Forum Infect Di. 2019;6(10):ofz380.
   PubMed Web of Science ®Google Scholar
• Liao GY, Li RC, Li CG, et al. Safety and immunogenicity of inactivated poliovirus vaccine made from Sabin strains: a phase ll, randomized, positive-controlled trial. J Infec Dis. 2012;205(2):237–243.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Yan DM, Zhu SL, et al. An insight into recombination with enterovirus specific C and nucleotide G-480 reversion from the viewpoint of neurovirulence of vaccine-derived polioviruses. Sci Rep. 2015;5(1):17291.
   PubMed Web of Science ®Google Scholar
• Yan DM, Zhang Y, Zhu SL, et al. Limited and localized outbreak of newly emergent type 2 vaccine-derived poliovirus in Sichuan, China. Clin Vaccine Immunol. 2014;21(7):1012–1018.
   PubMedGoogle Scholar
• Wen N, Fan CX, Fu JP, et al. Enhanced surveillance of acute flaccid paralysis following importation of wild poliovirus in Xinjiang Uygur autonomous region, China. BMC Infect Dis. 2014;14(113):1–8.
   PubMed Web of Science ®Google Scholar
• Wang HB, Yu WZ, Wang XQ, et al. An outbreak following importation of wild poliovirus in Xinjiang Uyghur Autonomous Region, China, 2011. BMC Infect Dis. 2015;34:15.
   Google Scholar
• Luo HM, Zhang Y, Wang XQ, et al. Identification and control of a poliomyelitis outbreak in Xinjiang, China. N Engl J Med. 2013;369(21):1981–1990.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Biologicals Unit. (1995). Manual of laboratory methods for potency testing of vaccines used in the WHO Expanded Programme on Immunization. World Health Organization. https://apps.who.int/iris/handle/10665/58651.
   Google Scholar
• Sun MB, Li CG, Xu WB, et al. Immune serum from Sabin inactivated poliovirus vaccine immunization neutralizes multiple individual wild and vaccine-derived polioviruses. Clin Infect Dis. 2017;64(10):1317–1325.
   PubMed Web of Science ®Google Scholar
• Okayasu H, Sein C, Hamidi A, et al. Development of inactivated poliovirus vaccine from Sabin strains: a progress report. Biologicals. 2016;44(6):581–587.
   PubMed Web of Science ®Google Scholar
• Mbaeyi C, Wadood ZM, MJourn TM, et al. Strategic response to an outbreak of circulating vaccine-derived poliovirus type 2 - Syria, 2017–2018. MMWR Morb Mortal Wkly Rep. 2018;67(24):690–694.
   PubMed Web of Science ®Google Scholar
• Blake IM, Salort MP, Molodecky NA, et al. Type 2 poliovirus detection after global withdrawal of trivalent oral vaccine. N Engl J Med. 2018;379(9):834–845.
   PubMed Web of Science ®Google Scholar
• Konopka-Anstadt JL, Campagnoli R, Vincent A, et al. Development of a new oral poliovirus vaccine for the eradication end game using codon deoptimization. Npj Vaccines. 2020;5(1):26.
   PubMed Web of Science ®Google Scholar
• Yeh MT, Bujaki E, Dolan PT, et al. Engineering the live-attenuated polio vaccine to prevent reversion to virulence. Cell Host Microbe. 2020;27(5):736–751.
   PubMed Web of Science ®Google Scholar
• Damme PV, Coster ID, Bandyopadhyay AS, et al. The safety and immunogenicity of two novel live attenuated monovalent (serotype 2) oral poliovirus vaccines in healthy adults: a double-blind, single-centre phase 1 study. Lancet. 2019;394(10193):148–58.
   PubMed Web of Science ®Google Scholar